Tirzepatide 3-month results: what TikTok shows vs. trial data

What did @lachumina713 actually say?

Honestly? Not much we can work with. The transcript captured what appears to be background audio or music lyrics, not medical commentary. The words "When I'm on top, then you go hate me just a little bit" are not a health claim. They are a song snippet. The actual content of this video, a three-month tirzepatide process, is described only in the caption: "Les comparto mi proceso de 3 meses con trizepatide" (I share my 3-month process with tirzepatide). So we are fact-checking a category of claim, personal weight loss testimony using GLP-1 medications, rather than specific spoken assertions.

The creator also tags another account, @Graciela-Solis, with "Mandate mensaje" (send her a message), which reads like a referral to a seller or provider. That detail matters. It shifts this from personal diary content into something closer to a promotional referral, whether intentional or not.

Does the science back this up?

Three months of tirzepatide for weight loss is a real, documented timeframe where meaningful results can occur. The SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) showed that participants on 15mg tirzepatide lost an average of 20.9% of body weight over 72 weeks, with significant losses visible by week 12. So a 3-month progress video is not nonsense.

What the science cannot confirm is any individual's specific results. GLP-1 and GIP dual agonists like tirzepatide work by suppressing appetite, slowing gastric emptying, and improving insulin sensitivity. They do not work the same way for everyone. Factors including baseline weight, adherence, diet, sleep, and metabolic health all shape outcomes. A creator showing progress at 3 months may be having a genuinely positive response, or they may be in an early honeymoon phase before plateauing. Neither conclusion can be drawn from a caption alone.

What did they get wrong (or right)?

The caption spells the drug "trizepatide" rather than "tirzepatide." That is a minor spelling error and likely not intentional misinformation, but it does mean anyone searching that hashtag may not find accurate medical information alongside it. Small error, real consequence for health literacy online.

More worth scrutinizing is the referral mechanic. Tagging someone and saying "send her a message" in the context of a weight loss drug video raises questions. Is @Graciela-Solis a licensed prescriber? A compounding pharmacy contact? A reseller? Tirzepatide is a prescription medication. It cannot and should not be obtained outside a legitimate prescribing relationship. Compounded tirzepatide is also not equivalent to FDA-approved Zepbound or Mounjaro. The FDA has flagged compounded versions for quality and safety concerns. If this tag is pointing viewers toward a non-clinical source, that is a real problem regardless of how positive the results look.

What should you actually know?

If you watched this video and thought about starting tirzepatide, here is what actually matters. First, tirzepatide requires a prescription from a licensed provider who has reviewed your medical history. Second, the SURMOUNT program trials excluded people with certain heart conditions, eating disorders, and other contraindications. What works on camera for one person at 1.2K views is not a clinical recommendation for you.

Third, "process videos" on social media almost never show side effects. The clinical trial data shows that nausea, vomiting, diarrhea, and constipation are common, especially during dose escalation. Jastreboff et al. (2022) reported gastrointestinal adverse events in roughly 80% of participants at some point. You will rarely see that in a motivation montage.

• Tirzepatide is only legally available via prescription in the US.
• Compounded tirzepatide is not FDA-approved and carries unverified potency risks.
• Individual results vary significantly based on health history and dose tolerance.
• Three months is early. Long-term data from SURMOUNT trials covers 72 to 88 weeks.

The referral tag deserves its own scrutiny

"Mandate mensaje" to a tagged account in a GLP-1 weight loss post is a pattern regulators are watching. The FTC has increased enforcement around undisclosed affiliate relationships in health content. If the tagged account is selling or facilitating access to tirzepatide outside a formal telehealth structure, that is potentially unlawful. Viewers should treat any social media referral for prescription weight loss medication with real skepticism, and verify that any provider they contact is licensed, registered, and operating within their state's prescribing laws.